← Leaderboards
Anthony Joseph Garcia-Prats
Stellenbosch University
$2,250,973
Attributed
$3,051,155
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,051,155 · 2
By mechanism
R01$1,600,365 · 1
U01$1,450,790 · 1
Top collaborators
- Radojka Savic5 shared
Most similar at Stellenbosch University
Same institution · by research overlap
- Robin Mark Warren$521,206
- Charissa Camille Naidoo$357,782
- Marisa Klopper$318,264
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyDoseTreatment OutcomeTreatment DurationChildTreatment ProtocolsDrug Resistance In TuberculosisPharmaceutical PreparationsRegimenSeverity Of IllnessTuberculosis DrugsTuberculosisTuberculosis TreatmentWeightChildhoodDrug KineticsNutritional StatusFutureAdultAdherenceFormulationBiological AvailabilityBaseAdverse Event
Grant awards (7)
Re-evaluating the Duration in Children of TB Treatment (REDUCE TB): A Phase 2 Duration Randomized Trial$1,286,549
U01 · FY2025 · AI · contact PI
Re-evaluating the Duration in Children of TB Treatment (REDUCE TB): A Phase 2 Duration Randomized Trial$164,241
U01 · FY2025 · AI · contact PI
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment$299,535
R01 · FY2019 · HD · contact PI
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment$311,733
R01 · FY2018 · HD · contact PI
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment$319,701
R01 · FY2017 · HD · contact PI
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment$325,815
R01 · FY2016 · HD · contact PI
Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment$343,581
R01 · FY2015 · HD · contact PI